All In Biotech

Drug Trial Radar · NCT00368537

Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin Infections

A Multicenter, Randomized, Open-Label Comparison of the Safety And Efficacy of Tigecycline With That of Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Complicated Skin And Skin Structure Infections

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 550 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

550

Actual

Start

Sep 2006

Primary completion

Sep 2008

Study completion Sep 2008

Sponsor

Sponsor type
Industry
First posted
Aug 24, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the safety and efficacy of the antibiotic tigecycline with other antibiotics, ampicillin-sulbactam, and amoxicillin-clavulanate in the treatment of a complicated skin and/or skin structure infection (cSSSI).

Conditions

  • Skin Diseases, Bacterial

Interventions

  • TigecyclineDrug

    Treatment A: Tigecycline every 12 hours intravenous (IV) (an initial dose of 100 mg followed by 50 mg every 12 hours)

  • ampicillin-sulbactamDrug

    Ampicillin-sulbactam: 1.5 g (1 g ampicillin plus 0.5 g sulbactam) to 3 g (3 g ampicillin plus 1 g sulbactam) intravenous (IV) every 6 hrs or Amoxicillin-clavulanate: 1.2 g (1000 mg amoxicillin plus 200 mg clavulanate) IV every 6 to 8 hrs. A glycopeptide antibiotic (either vancomycin 1 g IV every 12 hrs or teicoplanin IV loading dose of 400 mg the first day followed by a maintenance dose of 200 mg daily) may be added to the aminopenicillin/betalactamase inhibitor regimen if infection with methicillin-resistant staphylococcus aureus (MRSA) is suspected or confirmed within the first 72 hrs of enrollment. If culture results fail to show a resistant organism, use of the glycopeptide may be discontinued.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Clinically Evaluable (CE) Patients With Clinical Response of Cure at the Test-of-cure (TOC) VisitTime frame: up to 6 weeks

Locations

57 sites in 12 countries. Site status is shown where the registry gives one.

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Jonesboro, Arkansas

  • Site not named

    Chula Vista, California

  • Site not named

    Mission Viejo, California

  • Site not named

    National City, California

  • Site not named

    Denver, Colorado

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Orlando, Florida

  • Site not named

    Vero Beach, Florida

  • Site not named

    Fort Gordon, Georgia

  • Site not named

    Idaho Falls, Idaho

  • Site not named

    Decatur, Illinois

  • Site not named

    Naperville, Illinois

  • Site not named

    Springfield, Illinois

  • Site not named

    Topeka, Kansas

  • Site not named

    Cambridge, Massachusetts

  • Site not named

    Worcester, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    Lincoln, Nebraska

  • Site not named

    Hackensack, New Jersey

  • Site not named

    Neptune City, New Jersey

  • Site not named

    Buffalo, New York

  • Site not named

    Elmira, New York

  • Site not named

    New Hyde Park, New York

  • Site not named

    Columbus, Ohio

  • Site not named

    Lima, Ohio

  • Site not named

    Lansdale, Pennsylvania

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Fort Worth, Texas

  • Site not named

    Houston, Texas

  • Site not named

    Québec, Canada

  • Site not named

    Winnipeg, Manitoba, Canada

  • Site not named

    Chicoutimi, Quebec, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Sherbrooke, Quebec, Canada

  • Site not named

    Trois-Rivières, Quebec, Canada

  • Site not named

    Saskatoon, Saskatchewan, Canada

  • Site not named

    Hong Kong, Hong Kong

  • Site not named

    Ramat Gan, Israel

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.